Filter
351
Text search:
guidelines
for
pharmacovigilance
Featured
46
107
Language
Document type
165
71
43
32
24
8
3
3
1
1
Countries
20
15
14
13
13
12
10
10
9
9
8
8
7
7
7
7
5
5
5
5
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
180
42
9
8
6
6
6
Toolboxes
44
43
30
29
20
18
6
5
3
2
2
2
1
1
1
1
1
The National Action Plan (NAP) has been developed based on the model recommended in the global Action Plan. Local data on on-going interventions were collected from technical informants in the various areas of work. These were analysed using the policy framework provided by the AMR policy document.
...
Waste Management & Research 39(1) DOI: 10.1177/0734242X211029175
Drugs & Therapy Perspectives vol.36 (2020) 6
1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization
Against this background of nearly 20 years of experience of research, development and
improvement in patient safety, the role of incident and adverse event reporting, as well as the
benefits that derive from it, is still a work in progress.This document has two main purposes:
• to provide an up
...
El grupo de Farmacovigilancia de la red Panamericana para la Armonización Farmacéutica (PARF) de la Organización Panamericana de la Salud (OPS), ha desarrollado este documento desde la visión OPS/OMS, considerando que la farmacovigilancia es un componente esencial de los programas de salud públ
...
Interim policy guidance
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid,
...
Accessed November 2017
